Johnson & Johnson

Johnson & Johnson

JNJ

$266.17

Updated: 04/11/2026, 13:12:19

Market Cap
$640.75B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

USD
NYSE
CEO: Joaquin Duato
Employees: 141,700
https://www.jnj.com
Asset Summaries
Latest generated summaries for JNJ

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
JNJ-10-k-fy2025.html3.5 MBtext/htmlENFiled 11/02/2026Period ended 28/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 60 KPI observations

Revenue

$94.2B

FY 2025 · Reported

Net income

$26.8B

FY 2025 · Reported

Gross margin

67.9%

FY 2025 · Calculated

Free cash flow

$19.7B

FY 2025 · Calculated

R&D intensity

0.1%

FY 2025 · Calculated

Share repurchases

$6.0B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

MedTech product fields
DARZALEX largest product, ~15% of revenues with Genmab royalties
TREMFYA third largest product

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Innovative Medicine therapeutic areas

Innovative Medicine focused on Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolic

99%
Source evidence
“The Innovative Medicine segment is focused on the following therapeutic areas: Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolic.”

Two business segments

Two segments: Innovative Medicine and MedTech

99%
Source evidence
“The Company is organized into two business segments: Innovative Medicine and MedTech.”

Two reportable segments

Innovative Medicine and MedTech

99%
Source evidence
“The Company is organized into two business segments: Innovative Medicine and MedTech.”

MedTech portfolio areas

Cardiovascular, Orthopaedics, Surgery, Vision

98%
Source evidence
“The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopaedics, surgery, and vision”

Two operating segments

Two operating segments: Innovative Medicine and MedTech

98%
Source evidence
“The Company faces substantial competition in its two operating segments and in all geographic markets.”

Distribution channels

IM products distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals; MedTech to wholesalers, hospitals and retailers

95%
Source evidence
“Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment ... distributed to wholesalers, hospitals and retailers”

MedTech product fields

MedTech includes products used in the Surgery, Orthopaedic, Cardiovascular and Vision fields

99%
Source evidence
“The MedTech segment includes a broad portfolio of products used in the Surgery, Orthopaedic, Cardiovascular and Vision fields.”

DARZALEX largest product, ~15% of revenues with Genmab royalties

DARZALEX/DARZALEX FASPRO ~15.0% of FY2025 revenues; $2.4B royalties to Genmab; US patents expire 2029

97%
Source evidence
“Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO..., accounted for approximately 15.0% of the Company's total revenues for fiscal 2025.”

TREMFYA third largest product

TREMFYA ~5.5% of FY2025 revenues, +40.5% growth; US patent projected 2031 expiry

95%
Source evidence
“Sales of the Company’s third largest product, TREMFYA (guselkumab), accounted for approximately 5.5% of the Company's total revenues for fiscal 2025.”

FY2025 segment sales

Worldwide sales $94.2B (+6.0%); Innovative Medicine $60.4B (+6.0%)

98%
Source evidence
“In 2025, worldwide sales increased 6.0% to $94.2 billion... Innovative Medicine segment sales in 2025 were $60.4 billion, an increase of 6.0% from 2024”

Operations and dependencies

FX hedging sensitivity

A 10% USD appreciation/depreciation changes forward contract value by ~$0.2B/-$0.3B; 1% rate spread change affects swaps ~$1.5B

93%
Source evidence
“A 10% appreciation of the U.S. Dollar from the December 28, 2025 market rates would increase the unrealized value of the Company’s forward contracts by approximately $0.2 billion.”

63 manufacturing facilities

Subsidiaries operate 63 manufacturing facilities with sourcing from thousands of suppliers worldwide

97%
Source evidence
“The Company’s subsidiaries operate 63 manufacturing facilities as well as sourcing from thousands of suppliers around the world.”

Reliance on third-party manufacturers and suppliers

Relies on third parties to manufacture and supply certain raw materials, component parts and products

95%
Source evidence
“The Company relies on third parties to manufacture and supply certain of our raw materials, component parts and products.”

Employees worldwide

Approximately 138,200 employees worldwide

99%
Source evidence
“The Company has approximately 138,200 employees worldwide”

Approximately 138,200 employees worldwide

~138,200 employees worldwide

98%
Source evidence
“Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide”

Positioning and strategy

FY2025 acquisitions cash outflow

FY2025 acquisitions net of cash acquired $17,541M plus $385M acquired IPRD/milestones

98%
Source evidence
“Acquisitions, net of cash acquired (Note 18)(17,541)(15,146)— ... Acquired in-process research and development/related milestones (Note 18)(385)(1,783)(470)”

Intra-Cellular Therapies acquisition

Acquired Intra-Cellular Therapies, Inc. for ~$14.5B, closed April 2, 2025, funded partly by ~$9.2B senior unsecured notes

97%
Source evidence
“The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.5 billion which closed on April 2, 2025”

Intra-Cellular Therapies acquisition (CAPLYTA)

Intra-Cellular Therapies acquired April 2, 2025; CAPLYTA contributed $700M in 2025

95%
Source evidence
“CAPLYTA (lumateperone) acquired with the Intra-Cellular Therapies (Intra-Cellular) acquisition on April 2, 2025”

Planned Orthopaedics separation (DePuy Synthes)

In October 2025 J&J announced intention to separate its Orthopaedics business (DePuy Synthes), targeted completion within 18 to 24 months

98%
Source evidence
“In October 2025, the Company announced its intention to separate its Orthopaedics business. The Company intends to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months”

R&D investment and new-product contribution

$14.7B R&D in 2025; products introduced in past 5 years ~25% of 2025 sales

95%
Source evidence
“New products introduced within the past five years accounted for approximately 25% of 2025 sales. In 2025, $14.7 billion was invested in research and development”

Planned Orthopaedics separation

Company announced intention in Oct 2025 to separate Orthopaedics business, targeted within 18-24 months

98%
Source evidence
“In October 2025, the Company announced its intention to separate its Orthopaedics business... targeted completion within 18 to 24 months after the initial announcement.”

Risks, financing, and outlook

Total borrowings 2025 vs 2024

Total borrowings $47.9B (2025) vs $36.6B (2024); net debt $27.8B; debt 37.0% of total capital

97%
Source evidence
“Total borrowings at the end of 2025 and 2024 were $47.9 billion and $36.6 billion, respectively.”

$10B 364-day credit facility

New 364-day Credit Facility of $10 billion secured June 2025, expiring June 24, 2026

95%
Source evidence
“In June 2025, the Company secured a new 364-day Credit Facility of $10 billion, which expires on June 24, 2026.”

DePuy Synthes trademark reclassification to indefinite-lived

$1.7 billion of DePuy Synthes trademarks reclassified from definite-lived to indefinite-lived in connection with planned separation; concluded not impaired

97%
Source evidence
“Therefore, $1.7 billion of trademarks associated with the DePuy Synthes brand were reclassified from definite lived to indefinite lived.”

Provision for taxes on income

Tax provision $5,777M (2024: $2,621M; 2023: $1,736M); ASU 2023-09 income tax disclosures adopted FY2025

95%
Source evidence
“Provision for taxes on income (Note 8)5,7772,6211,736 ... The Company adopted this standard prospectively for fiscal year 2025.”

IRA Medicare pricing from 2026

IRA subjected certain products to government-established pricing beginning in 2026 and may subject additional products in the future

96%
Source evidence
“the Inflation Reduction Act of 2022 (IRA) has changed Medicare Part D benefit design and has subjected certain of the Company's products to government-established pricing beginning in 2026 and may subject additional products in the future”

Loss of patent exclusivity risk (Innovative Medicine)

Loss of patent exclusivity often followed by substantial sales reduction as generic and biosimilar competitors enter

97%
Source evidence
“For the Company’s Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products and enter the market.”

STELARA biosimilar erosion

STELARA ~6.5% of FY2025 revenues, sales -41.3% due to biosimilar competition

97%
Source evidence
“The Company expects continued launches of biosimilar versions of STELARA globally which will continue to negatively impact the Company’s sales of STELARA.”

Expected OPSUMIT generic competition in 2026

Generic competition for OPSUMIT expected in 2026

90%
Source evidence
“The Company expects generic competition for OPSUMIT in 2026, which would likely result in a significant reduction in future sales.”

Counterfeit product risk

Distribution channels vulnerable to illegal counterfeiting in a growing number of markets and over the Internet

90%
Source evidence
“Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet.”

340B program exposure

Increased third-party utilization of the 340B program may negatively impact financial performance

88%
Source evidence
“increased third-party utilization of the 340B Federal Drug Discount Program from expanded interpretations of the statute and program abuse may have a negative impact on the Company's financial performance”

Material exposure graph

DARZALEX
Revenue Exposure

DARZALEX/DARZALEX FASPRO is ~15% of total revenues and grew 23.0% in 2025; Genmab-licensed patents expire in US in 2029 with 12-20% royalty obligation.

Relevance 95·Dependency 75·Confidence 97
Source evidence
“Royalty rate ranges from 12% to 20% of total DARZALEX net sales. For the fiscal 2025 and 2024, royalty amounts to Genmab were approximately $2.4 billion and $2.0 billion, respectively.”
STELARA biosimilars
Competitive Exposure

Biosimilar competition drove STELARA sales down 41.3% to $6.1B and cut 6.2% from worldwide sales growth; further launches expected.

Relevance 90·Dependency 60·Confidence 97
Source evidence
“the negative impact of the STELARA sales decline, due to biosimilar competition, was approximately 6.2%, 7.6% and 4.4% on worldwide, U.S. and international operational sales”
Inflation Reduction Act of 2022
Revenue Exposure

IRA government-established Medicare pricing beginning 2026 and Part D redesign could reduce U.S. Innovative Medicine sales.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“change to Medicare Part D could have a negative impact on U.S. Innovative Medicine sales.”
Three wholesalers
Customer Exposure

Three wholesalers distribute products for both segments and represent ~48% of total gross revenues, creating channel concentration risk.

Relevance 85·Dependency 60·Confidence 95
Source evidence
“the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8%, 15.5% and 11.1% of the total gross revenues”
Talc body powders (JOHNSON’S Baby Powder)
Legal Exposure

Numerous talc lawsuits could require significant payments potentially in excess of accruals.

Relevance 85·Dependency 60·Confidence 96
Source evidence
“the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder”
Oncology
Revenue Exposure

Oncology is a named therapeutic area of the Innovative Medicine segment driving prescription product sales.

Relevance 85·Dependency 40·Confidence 90
Source evidence
“The Innovative Medicine segment is focused on the following therapeutic areas: Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolic.”
Third-party manufacturers and suppliers
Supplier Dependency

Reliance on third-party manufacturers for certain raw materials, components and products creates disruption and cost risk.

Relevance 80·Dependency 65·Confidence 93
Source evidence
“Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business.”
Hospitals and healthcare professionals
Revenue Exposure

Both segments distribute through hospitals, wholesalers and healthcare professionals, making these channels key to revenue.

Relevance 80·Dependency 50·Confidence 90
Source evidence
“distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use”
Intra-Cellular Therapies, Inc.
Revenue Exposure

$14.5B acquisition closed April 2, 2025 drove ~$11.3B increase in total borrowings and higher net debt.

Relevance 75·Dependency 60·Confidence 95
Source evidence
“The increase in the borrowings was primarily due to the issuance of new debt in the fiscal first quarter of 2025.”
Acquired in-process R&D pipeline
Technology Dependency

Indefinite-lived purchased IPR&D of $15,619M and ongoing IPR&D acquisitions/milestones underpin the future Innovative Medicine pipeline.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“Purchased in-process research and development15,61912,281”
Medicare Part D redesign
Cost Driver

Medicare Part D redesign repeatedly cited as an offset to growth across ERLEADA, IMBRUVICA, STELARA, INVEGA, OPSUMIT and UPTRAVI.

Relevance 75·Dependency 50·Confidence 90
Source evidence
“Growth of ERLEADA (apalutamide) was primarily due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign.”
340B Federal Drug Discount Program
Revenue Exposure

Expanded interpretations and program abuse of 340B discounts may hurt financial performance.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“increased third-party utilization of the 340B Federal Drug Discount Program from expanded interpretations of the statute and program abuse may have a negative impact on the Company's financial performance”
Genmab A/S
Technology Dependency

Genmab owns two DARZALEX patent families exclusively licensed to Janssen Biotech; royalties of ~$2.4B in 2025 at 12-20% of net sales.

Relevance 70·Dependency 55·Confidence 95
Source evidence
“Genmab A/S owns two patent families related to DARZALEX, and Janssen Biotech, Inc. ... has an exclusive license to those patent families.”
Cardiovascular (MedTech)
Revenue Exposure

Cardiovascular is a disclosed MedTech product field contributing to MedTech revenue.

Relevance 70·Dependency 30·Confidence 90
Source evidence
“The MedTech segment includes a broad portfolio of products used in the Surgery, Orthopaedic, Cardiovascular and Vision fields.”
Surgery (MedTech)
Revenue Exposure

Surgery is a disclosed MedTech product field used by physicians, nurses, hospitals and clinics.

Relevance 70·Dependency 30·Confidence 90
Source evidence
“used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics”
U.S. Dollar
Cost Driver

Company hedges FX via forwards and swaps; sensitivities quantified at ±$0.2B/-$0.3B for 10% USD move.

Relevance 65·Dependency 55·Confidence 90
Source evidence
“Conversely, a 10% depreciation of the U.S. Dollar from the December 28, 2025 market rates would decrease the unrealized value of the Company’s forward contracts by approximately $0.3 billion.”
Taxation
Cost Driver

Tax provision more than doubled to $5,777M in FY2025 from $2,621M, materially affecting net earnings.

Relevance 60·Dependency 40·Confidence 85
Source evidence
“Provision for taxes on income (Note 8)5,7772,6211,736”
SPRAVATO
Demand Driver

SPRAVATO grew 57.4% to $1,696M on increased physician and patient demand, a key Neuroscience growth driver.

Relevance 60·Dependency 35·Confidence 90
Source evidence
“Growth of SPRAVATO (esketamine) was driven by continued increased physician and patient demand.”
SIMPONI biosimilars
Legal Exposure

At least two SIMPONI biosimilars pursuing US approval, which would likely significantly reduce future sales.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“At least two biosimilars are pursuing regulatory approval for a SIMPONI biosimilar in the United States, which would likely result in a significant reduction in future sales.”
Full company information
Latest profile, trading, valuation, and identifier data stored for JNJ.
Share price
$266.17
Market cap
$640.75B
Exchange
NYSE
Currency
USD
CEO
Joaquin Duato
Employees
141,700
IPO date
02/01/1962
Beta
0.235
Last dividend
$0.00
Day range
$265.29 – $271.07
52-week range
$185.12 – $282.02
1-day performance
-1.62%
1-year performance
43.78%
Current drawdown (1Y)
-5.62%
CIK
0000200406
CUSIP
478160104
ISIN
US4781601046
Created
07/12/2025, 04:53:05
Last update
04/11/2026, 13:12:19

Track Johnson & Johnson with an AI analyst

See which prediction-market events move JNJ, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to JNJ from your Railway `news_articles` table.

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Business Wire • STOCK • 15/06/2026, 08:00:00

A $650,000 Portfolio That Could Send You to the Super Bowl Every Year

247 Wallst • STOCK • 13/06/2026, 12:22:44

The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I'm Loading Up on Anyway

24/7 Wall Street • STOCK • 11/06/2026, 15:08:00

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Business Wire • STOCK • 11/06/2026, 09:45:00

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

PRNewsWire • STOCK • 11/06/2026, 04:03:00

I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow

24/7 Wall Street • STOCK • 10/06/2026, 14:39:11

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Business Wire • STOCK • 10/06/2026, 13:22:00

Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond

24/7 Wall Street • STOCK • 10/06/2026, 13:20:58

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

WSJ • STOCK • 10/06/2026, 08:20:00

J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition

Zacks Investment Research • STOCK • 09/06/2026, 14:20:25

JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?

Zacks Investment Research • STOCK • 09/06/2026, 14:06:16

Will Johnson & Johnson Stock Hit $300 This Year?

24/7 Wall Street • STOCK • 09/06/2026, 12:06:47